We hope you find what you’re looking for. You can email us if you need additional help.
Yesterday, Optimi Health announced an important MDMA and psilocybin supply agreement for Australians approved under the country’s Authorised Prescribers Scheme. Our new long-term relationship with Mind Medicine Australia positions Optimi as the primary supplier to Australia’s newly regulated psychedelic market.
The announcement follows a national reclassification of MDMA and psilocybin for therapeutic uses in Australia as a result of the years-long effort of Mind Medicine Australia and its dedicated supporters Highlights: • Signed Purchase Orders with Mind Medicine Australia to
Full end-to-end, GMP manufacturing of OPTI-MHCL solidifies the Company’s plan to address the global demand for MDMA in 2023 and beyond Highlights: Vancouver, British Columbia – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), and
Regulator Filings
Legal Counsel: Norton Rose Fulbright
Auditor: Smythe CPA
Transfer Agent: Endeavor Trust
Corporate Visibility & Investor Relations: Kydder Group
Trading Symbol: CSE: OPTI | OTC:OPTHF |
FRA: 8BN
CUSIP Number: 68405H100
ISIN Number: CA68405H1001
WKN: A2QQEL
Issued & Outstanding: (30/06/2022) 80,451,883
Incorporated: BC / May 27, 2020
Year End: September 30th
